Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- SLGL
- Price
- 57.50
- Stock movement up
- +0.92 (2.31%)
- Company name
- Sol Gel Technologies Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 113.38M
- Ent value
- 110.59M
- Price/Sales
- 9.68
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 660.61%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SLGL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.68 |
| Price to Book | - |
| EV to Sales | 9.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.79M |
| EPS (TTM) | -3.23 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 18.97M |
| Gross profit (TTM) | 18.29M |
| Operating income (TTM) | 7.91M |
| Net income (TTM) | -8.99M |
| EPS (TTM) | -3.23 |
| EPS (1y forward) | -6.60 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.43% |
| Operating margin (TTM) | 41.71% |
| Profit margin (TTM) | -47.37% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.71M |
| Net receivables | 9.85M |
| Total current assets | 31.65M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.28M |
| Total assets | 34.59M |
| Accounts payable | 828.00K |
| Short/Current long term debt | 1.08M |
| Total current liabilities | 6.15M |
| Total liabilities | 8.56M |
| Shareholder's equity | 26.03M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.52% |
| Return on Assets | -25.98% |
| Return on Invested Capital | -33.88% |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 39.33 |
| Daily high | 40.70 |
| Daily low | 39.25 |
| Daily Volume | 14K |
| All-time high | 171.50 |
| 1y analyst estimate | 50.00 |
| Beta | 1.38 |
| EPS (TTM) | -3.23 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Mar 2026 |
Downside potential
Loading...
Downside potential data
| SLGL | S&P500 | |
| Current price drop from All-time high | -66.47% | -0.89% |
| Highest price drop | -97.61% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -91.82% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
113.38M
Marketcap category
Small-cap
Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Employees
34
Website
Investor relations
-
SEC filings
CEO
Alon Seri-Levy
Country
USA
City
Ness Ziona
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page